DE69834267D1 - Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen - Google Patents

Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen

Info

Publication number
DE69834267D1
DE69834267D1 DE69834267T DE69834267T DE69834267D1 DE 69834267 D1 DE69834267 D1 DE 69834267D1 DE 69834267 T DE69834267 T DE 69834267T DE 69834267 T DE69834267 T DE 69834267T DE 69834267 D1 DE69834267 D1 DE 69834267D1
Authority
DE
Germany
Prior art keywords
apoa
agonists
apolipoprotein
native
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69834267T
Other languages
English (en)
Other versions
DE69834267T2 (de
Inventor
Jean-Louis Dasseux
Renate Sekul
Klaus Buttner
Isabelle Cornut
Gunther Metz
Jean Dufourcq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69834267D1 publication Critical patent/DE69834267D1/de
Publication of DE69834267T2 publication Critical patent/DE69834267T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DE69834267T 1997-09-29 1998-09-28 Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen Expired - Fee Related DE69834267T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/940,136 US6518412B1 (en) 1997-09-29 1997-09-29 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US940136 1997-09-29
PCT/US1998/020329 WO1999016409A2 (en) 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Publications (2)

Publication Number Publication Date
DE69834267D1 true DE69834267D1 (de) 2006-05-24
DE69834267T2 DE69834267T2 (de) 2007-01-04

Family

ID=25474297

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834267T Expired - Fee Related DE69834267T2 (de) 1997-09-29 1998-09-28 Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen

Country Status (17)

Country Link
US (4) US6518412B1 (de)
EP (1) EP1039934B1 (de)
JP (1) JP2003525565A (de)
KR (1) KR100650975B1 (de)
CN (1) CN100345588C (de)
AT (1) ATE323510T1 (de)
AU (1) AU758307B2 (de)
CA (1) CA2304814A1 (de)
DE (1) DE69834267T2 (de)
ES (1) ES2263221T3 (de)
HU (1) HU225821B1 (de)
IL (1) IL135324A0 (de)
NO (1) NO20001601L (de)
NZ (1) NZ503720A (de)
PL (1) PL193662B1 (de)
RU (1) RU2222545C2 (de)
WO (1) WO1999016409A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP4794707B2 (ja) * 1998-11-17 2011-10-19 ソニー株式会社 端末装置、課金システム、データ処理方法
WO2001068852A2 (en) * 2000-03-13 2001-09-20 Amgen Inc. Apolipoprotein-a-i regulation of t-cell signalling
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2005068020A1 (en) * 2004-01-02 2005-07-28 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
WO2006034056A2 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
JP5091679B2 (ja) 2004-10-15 2012-12-05 アメリカ合衆国 マルチドメイン両親媒性ヘリックスペプチドおよびその使用方法
WO2006063132A2 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CN101489577B (zh) * 2006-06-01 2013-10-16 蒙特利尔心脏病学研究所 治疗心瓣膜病的方法和化合物
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
EP2041174A2 (de) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Neue, den lipidausstrom fördernde peptide
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
EP2081953A2 (de) * 2006-08-17 2009-07-29 The UAB Research Foundation Immunogene pcpa-polypeptide und ihre verwendung
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
DK2682400T5 (da) * 2007-08-28 2017-11-27 Uab Research Foundation Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US8936787B2 (en) * 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux
SI2396017T1 (sl) * 2009-02-16 2015-12-31 Cerenis Therapeutics Holding Sa Mimika apolipoproteina A-1
US8176412B2 (en) * 2009-08-25 2012-05-08 International Business Machines Corporation Generating formatted documents
RU2013112562A (ru) 2010-08-30 2014-10-10 Ф. Хоффманн-Ля Рош Аг Тетранектин-аполипопротеин а-i, содержащие его липидные частицы и его применение
SI2767546T1 (sl) * 2011-02-07 2019-03-29 Cerenis Therapeutics Holding Sa Lipoproteinski kompleksi in izdelava ter uporaba le-teh
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
CN103703023A (zh) 2011-08-25 2014-04-02 霍夫曼-拉罗奇有限公司 缩短的四连蛋白-载脂蛋白a-i融合蛋白，含有它的脂质颗粒，以及它们的用途
CN104250288B (zh) * 2013-06-28 2018-02-27 清华大学 两亲性α螺旋自组装肽及其应用
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (de) 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US5733879A (en) 1992-06-12 1998-03-31 N.V. Innogenetics, S.A. Peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5643757A (en) * 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
EP0755268A1 (de) * 1994-04-11 1997-01-29 Baylor College Of Medicine Zusammensetzungen und verfahren zur behandlung von erkrankungen durch gentherapie
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
AU9671498A (en) 1999-04-23
US6844327B2 (en) 2005-01-18
RU2222545C2 (ru) 2004-01-27
DE69834267T2 (de) 2007-01-04
US6518412B1 (en) 2003-02-11
HUP0003924A2 (hu) 2001-01-29
KR100650975B1 (ko) 2006-11-29
US20080050351A1 (en) 2008-02-28
NO20001601D0 (no) 2000-03-28
KR20010030806A (ko) 2001-04-16
WO1999016409A2 (en) 1999-04-08
US20030208059A1 (en) 2003-11-06
ATE323510T1 (de) 2006-05-15
HU225821B1 (en) 2007-10-29
PL193662B1 (pl) 2007-03-30
CA2304814A1 (en) 1999-04-08
ES2263221T3 (es) 2006-12-01
CN100345588C (zh) 2007-10-31
EP1039934A4 (de) 2002-11-27
IL135324A0 (en) 2001-05-20
HUP0003924A3 (en) 2005-12-28
US7250407B2 (en) 2007-07-31
AU758307B2 (en) 2003-03-20
EP1039934B1 (de) 2006-04-19
EP1039934A1 (de) 2000-10-04
CN1303298A (zh) 2001-07-11
NO20001601L (no) 2000-05-26
JP2003525565A (ja) 2003-09-02
NZ503720A (en) 2002-10-25
US20050148513A1 (en) 2005-07-07
PL358529A1 (en) 2004-08-09

Similar Documents

Publication Publication Date Title
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
ES2130177T3 (es) Tratamiento de poblaciones de celulas.
DE69839014D1 (de) Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen
ATE302267T1 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
WO2003104270A3 (en) GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES
DE69942365D1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DE69726884D1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
DE602004025265D1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
EP0815233A4 (de) Neue cytokinine aus vögeln und dafür codierende genetische sequenzen
FR2773079B1 (fr) Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
FR2792651A1 (fr) Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
BR9915537A (pt) Gene prv-1 e sua utilização
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee